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C oCCidioides immitis is a soil fungus endemic to the southwestern US and usually causes a self-limiting influenza-like illness in humans. In a small number of patients, hematological spread leads to disseminated coccidioidomycosis, which can affect nearly all organ systems in both immunologically normal and immunocompromised hosts. 10 Despite modern lifelong antifungal therapy, coccidiodomycosis is rarely cured. 5 Relevant to the field of neurosurgery, disseminated coccidioidomycosis may lead to fungal meningitis, cerebral or spinal abscess formation, and/or spinal osteomyelitis/discitis. 6, 8, 12 Meningitis due to coccidioidomycosis is often chronic and may lead to stroke due to vascular compromise at the skull base. 2, 7 Hydrocephalus due to arachnoid scarring is also a common sequela of coccidioidomycosis and may require CSF diversion via shunting.
1,3,4,9,11 One large series reported that approximately half of patients with coccidioidomycosis meningitis developed hydrocephalus. 4 The benefits of shunting must be appropriately weighed against the risk of placing indwelling hardware in a chronically infected patient. Due to a paucity of literature on the subject, we retrospectively reviewed our tertiary center's experience with managing coccidioidomycosis-related hydrocephalus.
Methods
We identified all patients treated at the Barrow Neurological Institute between 1990 and 2013 who were diagnosed with disseminated CNS coccidioidomycosis via an interdisciplinary registry after appropriate institutional review board approval was obtained from St. Joseph's Hospital and Medical Center. All patients had CSF serology Object. Coccidioidomycosis is a common fungal infection in the southwestern US. Hydrocephalus is a serious complication of cranial coccidioidomycosis, and the surgical management of coccidioidomycosis-related hydrocephalus has unique challenges. The authors reviewed their institutional experience with hydrocephalus in the setting of coccidioidomycosis.
Methods. The authors retrospectively identified 44 patients diagnosed with coccidioidomycosis-related hydrocephalus at their institution since 1990, who underwent a total of 99 shunting procedures. The authors examined patient demographics, type of shunt and valve used, pressure settings, failure rates, medical treatment, ventricular response to shunting, and other variables.
Results. The majority of patients were young (average age 37 years) men (male/female ratio 28:16) with a mean follow-up of 63 months. Patients of Asian and African descent were overrepresented in the cohort compared with regional demographic data. The overall shunt failure rate during follow-up was 50%, and the average number of revisions required if the shunt failed was 2.5 (range 1-8). Low to moderate draining pressures (mean 88 mm H 2 O) were used in this cohort. Fourteen patients received intrathecal antifungals, and a trend of initiating intrathecal therapy after need for a shunt revision was observed (p = 0.051). The majority of shunt failures (81%) were due to mechanical blockages in the drainage system. Most patients (59%) had at least partial persistent postoperative ventriculomegaly despite successful CSF diversion. Four patients (9%) died due to coccidioidomycosis during the follow-up period.
Conclusions. Coccidioidomycosis-related hydrocephalus more often affected young males in the study's cohort, especially those of African and Asian descent. Despite the best medical therapy, there was a high rate of shunt failure due to clogged catheters or valves due to the underlying disease process. Many patients continued to have ventriculomegaly even with adequate CSF diversion. The morbidity and mortality of this chronic disease process must be recognized by the treatment team, and patients should be appropriately counseled. and/or culture confirming the diagnosis of CNS coccidioidomycosis. The registry was used to identify all patients who underwent a CSF diversion procedure. Hospital, outpatient neurosurgical, and infectious disease clinic and radiological records were reviewed. Patient data such as age at diagnosis, race, gender, presentation, immunological status (normal vs compromised), radiographic findings, procedure(s) performed, antifungal therapies used, and morbidity/mortality were recorded. Each patient's clinical and radiographic records were analyzed for number of the CSF diversion operations, reasons for shunt failure, shunt pressure settings, and shunt valve brand, and the results were stratified by shunting procedure. We also sought to quantify the ventricular system response to shunting and divided postoperative imaging in those patients with full response to CSF diversion (normal postoperative ventricular size), partial response (decrease in ventricular size but chronic postoperative ventriculomegaly), or no response (stably enlarged ventricular size postoperatively despite a working shunt system and appropriate pressure settings). Postoperative imaging was not standardized; rather, it was directed by the treating physicians and tailored to patient symptoms. However, included postoperative imaging had to be performed at least 1 month after the index shunt procedure to allow time for ventricular reconfiguration. For statistical analysis, Fisher exact tests were used to compare categorical characteristics, while Student t-tests were used to assess continuous variables. A p value < 0.05 was considered statistically significant.
Results

Patient Demographics
We identified 44 patients with confirmed CNS coccidioidomycosis who underwent 99 CSF diversion procedures at our institution between 1990 and 2013. Their demographic information is presented in Table 1 . The majority of patients were young men (mean age 37 years; male/ female ratio 28:16). Only a small minority of patients were immunocompromised due to human immunodeficiency virus or chronic renal dialysis (n = 6, 13.6%). Patients of African/African American (OR 6.4 compared with Caucasian patients, 95% CI 2.1-19.0, p = 0.0002) and Asian/ Pacific Islander (OR 5.2 compared with Caucasian patients, 95% CI 1.5-18.4, p = 0.006) race were significantly overrepresented in the patient cohort when compared with Arizona census demographics (http://quickfacts.census. gov). The odds ratios for Native American and Hispanic heritage patients did not significantly differ from Caucasian patients (Table 2 ). All patients were maintained on chronic oral antifungal therapy. Fourteen patients (32%) were maintained on intrathecal antifungals at some point during their treatment. The mean clinical follow-up period after the first shunting operation was 63 months (range 4.1-315 months), during which 4 patients (9%) died due to coccidioidomycosis. One patient died as a result of ischemic stroke due to progressive basilar meningitis, 1 patient died of medical complications following transtentorial herniation due to acute shunt failure, and 2 patients were discharged to hospice due to progressive global neurological decline despite adequate CSF diversion.
Hydrocephalus and Shunting Outcomes
All patients, by inclusion criteria, underwent CSF diversion via shunt placement (Table 3 ). The majority of patients had ventriculoperitoneal shunts at their last follow-up (n = 40, 91%), although ventriculoatrial (n = 4, 9%) shunts were used in a small minority of patients. Low to moderate draining pressures were used in this cohort (mean draining pressure, 88 mm H 2 O), as measured by shunt setting recorded at last clinical follow-up. Valve selection was directed by individual surgeon preference, and these included valves from Hakim and Certas (both Codman Neuroscience Therapies, Raynham, MA), proGAV (Aesculap, Center Valley, PA), Strata (Medtronic Neurosurgery, Goleta, CA), and Polaris (Sophysa, Crown Point, IN). In the clinical record, valve brand was recorded for 86 of the 99 included operations. Only 4 of the 86 identified valves were nonprogrammable. With regard to ventricular response to shunting, all but 3 patients (n = 41) had pre-and postoperative CT and/or MR imaging to quantify ventricular response (examples are shown in Fig. 1) . A significant number of patients had a positive ventricular response to shunting (n = 17, 41%) with resolution of preoperative ventriculomegaly (Fig. 1A and B) . However, many patients experienced only a partial decrease (n = 15, 37%) in ventricular size with persistent postoperative ventriculomegaly despite a working shunt and attempts at alteration in valve setting (Fig.  1C and D) . A third subset of patients (n = 9, 22%) exhibited no significant decrease in ventricular size after shunting as assessed by long-term radiographic follow-up, despite a functional shunt system (Fig. 1E and F) . Therefore, a majority of patients (n = 24, 59%) had at least partial persistent ventriculomegaly after successful CSF diversion. There were no differences among the three ventricular response groups with regard to mean valve draining pressures, number of revisions required, or valve brands.
Shunt Failure and Revisions
Of the 44 patients, 22 (50%) experienced shunt fail- ure and underwent a total of 55 revision surgeries during clinical follow-up (Fig. 2) . The mean number of revision surgeries required if a patient suffered shunt failure was 2.5 (range 1-8). Of the 55 revision surgeries performed, 8 perioperative revisions were performed within 1 week of a prior shunt operation for either distal catheter preperitoneal placement (n = 3) or immediate valve revisions for unexpected low-pressure hydrocephalus (n = 5); these revisions were not included in further analyses. The median time to shunt failure was 4.0 months after surgery (range 0.5-168 months). The most common reason for shunt failure outside this perioperative window (n = 47) was due to clogging of the proximal or distal catheter or clogging within the valve mechanism (n = 38, 81%). A trend was observed (p = 0.051) toward the initiation of intrathecal antifungal therapy if a patient had ever experienced shunt failure when failure was considered a binary variable. However, no statistically significant interaction was found between intrathecal therapy use and increasing number of shunt revisions when the number of failures was analyzed as a continuous variable (Student t-test, 2-tailed, mean difference 0.93, p = 0.154, 95% CI −2.23−0.36). Valve brand was successfully assessed from the operative reports for 86 of the 99 procedures included in this series. We therefore removed unknown valve types (n = 13) and the above-mentioned perioperative revisions (n = 8) from our analysis of failure rate by valve brand, leaving 78 operations in which valve brand was known and follow-up data were available (Table 4) . No statistically significant differences were seen between valve brands when analyzed for shunt failure rates.
Discussion
In the present study, we have reported our retrospective experience with, to our knowledge, the largest published series of patients with hydrocephalus due to coccidioidomycosis. As demonstrated in other series, not all patients are at equal risk for the development of disseminated coccidioidomycosis, CNS involvement, and subsequent hydrocephalus. The majority of our patients were young males, and African or Asian heritage was associated with a significantly increased risk of coccidioidomycosis-related hydrocephalus. Most patients were not immunocompromised. The risk of shunt failure was high, and fully half of all patients in our series required 1 or more shunt revisions during the follow-up period. The 9% mortality rate during follow-up demonstrates the severity of this often-fatal disease process despite the best medical therapies. Our data also affirm several anecdotal observations about coccidioidomycosis-related hydrocephalus and its treatment.
First, the most common cause of shunt failure seen (81%) was mechanical clogging of the drainage system. Coccidioidomycosis can lead to significant proteinaceous debris; considerable biofilms or focal abscesses have been observed on catheters or within valve tapping chambers at the time of shunt revision.
3 Unfortunately, our data do not suggest a solution to improve shunt longevity, as we did not observe any differences among shunt valve brands. As almost all of our patients had ventriculoperitoneal shunts, our study was not appropriately powered to assess if other distal placement sites had a lower failure rate. Appropriate medical therapy with systemic antifungals is necessary in patients with hardware placed in a chronically infected space, and all of our patients were maintained on systemic antifungal medication. The role of intrathecal antifungals was not the focus of our study, and any benefit of intrathecal therapy on shunt failure rate may be masked by a selection bias whereby more severe cases receive intrathecal antifungals. Second, despite low drainage pressures and adequate CSF diversion, many patients with coccidioidomycosisrelated hydrocephalus experienced persistent ventriculomegaly after shunt surgery. The mechanism for this is not well elucidated, but it may include an alteration in the compliance of the ventricular wall or entire brain parenchyma due to infectious scarring or altered extraventricular CSF circulation. The clinical importance of this with regard to patient chronic headache or subtle cognitive function changes is unclear. However, it behooves the clinician treating patients with coccidioidomycosis-related hydrocephalus to assume that ventricular size does not necessarily indicate shunt failure or a functional shunt system.
The strengths of the current study include a relatively large number of patients with long follow-up (mean 63 months after shunt placement), and a serology-or cultureconfirmed diagnosis of CNS coccidioidomycosis in all patients. Our study was retrospective in nature and suffers from the inherent limitations of any such study. The treating physician chose the valve brand and setting used, and this may have introduced undetected confounding variables. Similarly, our study spanned treatment over 2 decades, and valve brands and treatment algorithms may have shifted over this time period. There was no standardized follow-up for patients, and so those individuals with more severe disease and uncontrolled symptoms may have been more likely to continue to follow up with the neurosurgical and infectious disease services, resulting in selection bias. Some patients who were successfully treated with antifungals may have become shunt independent, and this would have gone undetected in our retrospective review. We are a tertiary referral center, and our patient disease severity may not reflect that seen within a community setting. We were not able to accurately assess patient compliance with oral antifungals in this retrospective review, and this certainly may contribute to shunt failure. Lastly, we purposely only included patients who underwent CSF diversion, so we could not assess the number of patients who were successfully treated with temporary external CSF drainage and medical therapy and did not undergo permanent shunting. Similarly, we did not include patients who may have been treated successfully with endoscopic third ventriculostomy; however, our anecdotal experience is that third ventriculostomy is rarely successful in the setting of coccidioidomycosis (presumably due to basilar cisternal arachnoid scarring). As CSF characteristics at the time of surgery, such as protein, glucose, lactate, or other measurable values, were not routinely obtained on all patients, these lab values were not included in our study. A prospective study that examines the relationships of these values with shunt outcomes or ventricular response would be worthwhile.
Conclusions
Hydrocephalus is a serious cause of morbidity and mortality in patients with CNS coccidioidomycosis. Patients of African and Asian descent are at higher risk for the disease process. Shunt failure rates are high, usually due to obstruction. Not all patients' ventriculomegaly resolves, even with low-normal draining pressures. Multidisciplinary teams of neurosurgeons and infectious disease specialists are required to treat these challenging patients. * For the 78 shunting operations in which the valve brand was known and in which the patient did not undergo perioperative revision (< 1 week of having the shunt implanted). 
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